|
|
|
|
|
|
|
|
What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures
Objective
To review our 25-year experience with hyperthermic intra-peritoneal chemotherapy (HIPEC).
Background
Combining
cytoreductive surgery (CRS) and HIPEC as local treatments for
peritoneal carcinomatosis (PC) was proposed 25 years ago.
Methods
A
prospective database of all patients undergoing HIPEC for PC since 1989
was searched for clinicopathological data, 90-day morbidity and
mortality, and survival.
Results
Among
1,125 HIPEC procedures, PC origin was colorectal (342; 30%), ovarian
(271; 24%), pseudomyxoma peritonei (189; 17%), gastric (127; 11%),
malignant mesothelioma (84; 8%), or other (112; 10%). Between 2004–2009
(n = 321) and 2010–2015 (n = 560), the median peritoneal cancer index
decreased (11 vs. 8; P < 0.001), fewer patients underwent incomplete cytoreduction (CC2-3: 4% vs. 0.5%; P < 0.001), and more were included in randomized trials (5% vs. 16%; P < 0.001). Postoperative morbidity (52% vs. 50%, P = 0.672) was not different, but mortality significantly decreased (5% vs. 2%; P =
0.030). Median overall-survival was 42 months, and improved
significantly for each 5-year period except for 2006–2010 vs. 2011–2015 (P =
0.097). The 10-year survival without recurrence was 53%, 14%, 4%, 10%,
and 9% for pseudomyxoma, mesothelioma, ovarian, colorectal, and gastric
PC, respectively.
Conclusion
This
study demonstrated that CRS and HIPEC provide long-term survival
irrespective of PC origin, and survival improves with experience. J. Surg. Oncol.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.